Consensus Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
3.71 ^USD	0.00%		+1.09%	+21.64%

03-27	Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	CI
02-28	Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Atea Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7223a30ed83.aulPosfo4lm8feRV8vh0T3jSdV6WE9DYJwt_E2GL3RA.P9k_4YLc0Tv0OJEesLM6G1WnQD3aZ-KhXXMoTCu85HgcmHb4hIeYONoWtQ~eca10fca49d7519b3ee88ecd261ae216

Analyst Recommendations on Atea Pharmaceuticals, Inc.

JPMorgan Downgrades Atea Pharmaceuticals to Underweight From Neutral	23-08-10	MT
JPMorgan Adjusts Atea Pharmaceuticals Price Target to $8 From $12, Maintains Neutral Rating	23-03-16	MT
SVB Securities Adjusts Atea Pharmaceuticals' Price Target to $6 From $8, Keeps Market Perform Rating	23-01-27	MT
Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $4 From $7, Maintains Underweight Rating	23-01-24	MT
Morgan Stanley Raises Atea Pharmaceuticals' Price Target to $7 From $6, Maintains Underweight Rating	22-08-15	MT
JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutral Rating	22-03-02	MT
SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Perform Rating	22-03-01	MT
SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $10 from $11, Maintains Market Perform Rating	22-02-16	MT
Morgan Stanley Adjusts Atea Pharmaceuticals Price Target to $6 From $7, Reiterates Underweight Rating	22-02-01	MT
Morgan Stanley Downgrades Atea Pharmaceuticals to Underweight From Equal Weight, Adjusts PT to $7 From $14	22-01-06	MT
SVB Leerink Downgrades Atea Pharmaceuticals to Market Perform From Outperform, Sets $11 Price Target	21-11-18	MT
ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Atea Pharmaceuticals PT to $14 From $55, Maintains Equal Weight Rating	21-10-20	MT
ATEA PHARMACEUTICALS : SVB Leerink Adjusts Atea Pharmaceuticals PT to $20 From $60, Maintains Outperform Rating	21-10-20	MT
ATEA PHARMACEUTICALS : JPMorgan Downgrades Atea Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $16 from $61	21-10-20	MT
ATEA PHARMACEUTICALS : Morgan Stanley Downgrades Atea Pharmaceuticals to Equalweight From Overweight, Boosts Price Target to $55 From $37	21-10-05	MT
ATEA PHARMACEUTICALS : SVB Leerink Starts Atea Pharmaceuticals at Outperform with $60 Price Target	21-09-09	MT
ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $37 From $35, Maintains Overweight Rating	21-08-18	MT
ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $35 From $82, Maintains Overweight Rating	21-06-03	MT
Roche : Eyes New Location For COVID-19 Pill Study As UK Infection Rate Falls	21-04-21	MT
ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Atea Pharmaceuticals' Price Target to $82 from $49, Keeps Overweight Rating	21-04-06	MT
ATEA PHARMACEUTICALS : JP Morgan Adjusts Price Target on Atea Pharmaceuticals to $66 From $45, Maintains Overweight Rating	21-01-29	MT
ATEA PHARMACEUTICALS : Evercore ISI Initiates Coverage on Atea Pharmaceuticals With Outperform Rating	20-11-25	MT
ATEA PHARMACEUTICALS : JPMorgan Starts Atea Pharmaceuticals at Overweight With $45 Price Target	20-11-24	MT
ATEA PHARMACEUTICALS : William Blair Starts Atea Pharmaceuticals at Outperform	20-11-24	MT
ATEA PHARMACEUTICALS : Morgan Stanley Starts Atea Pharmaceuticals at Overweight With $49 Price Target	20-11-24	MT